JO3733B1 - استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة - Google Patents

استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة

Info

Publication number
JO3733B1
JO3733B1 JOP/2012/0065A JOP20120065A JO3733B1 JO 3733 B1 JO3733 B1 JO 3733B1 JO P20120065 A JOP20120065 A JO P20120065A JO 3733 B1 JO3733 B1 JO 3733B1
Authority
JO
Jordan
Prior art keywords
compound
pharmaceutical composition
expression
active agents
combination
Prior art date
Application number
JOP/2012/0065A
Other languages
English (en)
Inventor
Liu Ningshu
Schneider Claudia
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45894478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3733(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Application granted granted Critical
Publication of JO3733B1 publication Critical patent/JO3733B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)

Abstract

<span dir="RTL">يتعلق الاختراع الحالي بما يلي</span>: <span dir="RTL">استخدام مركب 2,3</span>-dihydroimidazo[1,2-c]quinazoline<span dir="RTL">، أو تركيبة دوائية تحتوي عليه، كعامل نشط مفرد، أو اتحاد من (أ) المركب المذكور أو تركيبة دوائية تحتوي على المركب المذكور و(ب) عامل نشط إضافي واحد أو أكثر، من أجل تحضير دواء لمعالجة أو الوقاية من السرطان؛ اتحاد من (أ) المركب المذكور و(ب) عامل نشط إضافي واحد أو أكثر؛ تركيبة دوائية تشتمل على المركب المذكور كعامل نشط مفرد من أجل معالجة سرطان الثدي؛ تركيبة دوائية تشتمل على اتحاد من (أ) المركب المذكور و(ب) عامل نشط إضافي واحد أو أكثر؛ استخدام علامة حيوية موجودة في تعديل إظهار</span> Bcl<span dir="RTL">، إظهار و/أو تنشيط عائلة</span> HER<span dir="RTL">، إرسال إشارة</span> PIK3CA <span dir="RTL">و/أو فقد</span> PTEN <span dir="RTL">للتنبؤ بالحساسية و/أو مقاومة مريض السرطان للمركب المذكور وتوفير اتحاد تآزري يعتمد على أساس منطقي كما تحدد هنا لزيادة الحساسية و/أو التغلب على المقاومة؛ و طريقة تحديد مستوى مكون من واحد أو أكثر من إظهار</span> Bcl<span dir="RTL">، إظهار و/أو تنشيط عائلة</span> HER<span dir="RTL">، إرسال إشارة</span> PIK3CA <span dir="RTL">و/أو فقد</span> PTEN.
JOP/2012/0065A 2011-04-05 2012-03-27 استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة JO3733B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11161142 2011-04-05

Publications (1)

Publication Number Publication Date
JO3733B1 true JO3733B1 (ar) 2021-01-31

Family

ID=45894478

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0065A JO3733B1 (ar) 2011-04-05 2012-03-27 استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة

Country Status (29)

Country Link
US (1) US10202385B2 (ar)
EP (1) EP2694069A1 (ar)
JP (1) JP6013446B2 (ar)
KR (1) KR102006033B1 (ar)
CN (1) CN103608018B (ar)
AP (1) AP3751A (ar)
AR (1) AR088730A1 (ar)
AU (2) AU2012238887A1 (ar)
BR (1) BR112013025517A2 (ar)
CA (1) CA2832120C (ar)
CL (1) CL2013002869A1 (ar)
CU (1) CU24349B1 (ar)
DO (1) DOP2013000224A (ar)
EA (1) EA027670B1 (ar)
EC (1) ECSP13013007A (ar)
GT (1) GT201300235A (ar)
IL (1) IL228435A0 (ar)
JO (1) JO3733B1 (ar)
MA (1) MA35015B1 (ar)
MX (1) MX2013011582A (ar)
MY (1) MY169532A (ar)
PE (1) PE20140571A1 (ar)
PH (1) PH12013502066A1 (ar)
SG (1) SG193577A1 (ar)
TN (1) TN2013000402A1 (ar)
TW (1) TWI639599B (ar)
UA (1) UA114177C2 (ar)
UY (1) UY33984A (ar)
WO (1) WO2012136549A1 (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2240451T3 (da) 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
DK2663309T3 (en) 2011-01-10 2017-06-19 Infinity Pharmaceuticals Inc METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CA2908776C (en) 2013-04-08 2021-08-10 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
US20150320755A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016087490A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
KR101665234B1 (ko) * 2015-02-10 2016-10-12 순천향대학교 산학협력단 골손실의 완화, 예방 또는 치료용 약학적 조성물 및 건강기능식품
KR20180013851A (ko) 2015-03-09 2018-02-07 바이엘 파마 악티엔게젤샤프트 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물
CN108884098B (zh) 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
IL263680B2 (en) 2016-06-24 2025-10-01 Infinity Pharmaceuticals Inc PI3K inhibitors for use in combination with a second therapeutic agent for the treatment, management or prevention of cancer
JP2019532922A (ja) 2016-09-23 2019-11-14 バイエル ファーマ アクチエンゲゼルシャフト Ｐｉ３ｋ−阻害剤の組み合わせ
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
US11253522B2 (en) * 2018-04-28 2022-02-22 The Regents Of The University Of California Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
US20210187134A1 (en) * 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1400959A (en) 1919-04-26 1921-12-20 Ste Chim Usines Rhone Process and apparatus for carrying out chemical reactions by catalysis
US1539891A (en) 1920-08-09 1925-06-02 Harry A Lewis Magnetic lifting device
US1450048A (en) 1921-09-24 1923-03-27 Mary S Patterson Nut lock
BE397809A (ar) 1932-08-25
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
WO2002069896A2 (en) * 2001-03-01 2002-09-12 Northwest Hospital Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation
WO2004005481A2 (en) * 2002-07-03 2004-01-15 The Trustees Of Columbia University In The City Of New York Methods for identifying modulators of mda-7 mediated apoptosis
SI1549652T1 (sl) 2002-09-30 2009-04-30 Bayer Healthcare Ag Kondenzirani azolpirimidinski derivati
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
JP5190233B2 (ja) 2006-09-01 2013-04-24 パナソニック株式会社 無線通信装置
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
US8859572B2 (en) * 2008-01-14 2014-10-14 Bayer Intellectual Property Gmbh Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
WO2009126172A1 (en) * 2008-04-11 2009-10-15 The Trustees Of Columbia University In The City Of New York Resistance to polyphenon e due to increased bcl-2 expression
KR101665042B1 (ko) 2008-04-18 2016-10-11 리타 파마슈티컬스 잉크. 소염성 골격군을 포함하는 화합물 및 사용 방법
US8071315B2 (en) * 2008-04-30 2011-12-06 Sanford-Burnham Medical Research Institute Detecting Bcl-B expression in cancer and uses thereof
FR2932483A1 (fr) * 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
US8128386B2 (en) 2008-06-26 2012-03-06 Hamilton Sundstrand Corporation Variable flow pumping system
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
JP5336306B2 (ja) 2008-10-20 2013-11-06 信越化学工業株式会社 レジスト下層膜形成方法、これを用いたパターン形成方法、及びレジスト下層膜材料
KR20170102379A (ko) 2009-05-14 2017-09-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 조류 종에서의 면역반응 강화
KR20130098155A (ko) * 2010-04-16 2013-09-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 치환된 ２,３-디히드로이미다조［１,２-ｃ］퀴나졸린-함유 조합물
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
HUE043473T4 (hu) 2010-12-22 2019-12-30 Bayer Ip Gmbh Fokozott immunválasz szarvasmarha fajokban
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CN104661846B (zh) 2012-09-21 2017-03-22 丰田自动车株式会社 混合动力车辆用驱动装置

Also Published As

Publication number Publication date
GT201300235A (es) 2014-08-27
MX2013011582A (es) 2014-05-01
PE20140571A1 (es) 2014-05-19
AU2012238887A1 (en) 2013-10-10
KR102006033B1 (ko) 2019-07-31
CU20130134A7 (es) 2014-01-29
SG193577A1 (en) 2013-10-30
CL2013002869A1 (es) 2014-07-18
AU2017203474B2 (en) 2019-03-21
ECSP13013007A (es) 2013-12-31
TN2013000402A1 (en) 2015-03-30
CN103608018A (zh) 2014-02-26
US10202385B2 (en) 2019-02-12
IL228435A0 (en) 2013-12-31
PH12013502066A1 (en) 2020-10-19
AP2013007147A0 (en) 2013-09-30
EP2694069A1 (en) 2014-02-12
TW201245202A (en) 2012-11-16
JP6013446B2 (ja) 2016-10-25
MY169532A (en) 2019-04-22
EA201301106A1 (ru) 2014-03-31
CA2832120A1 (en) 2012-10-11
CA2832120C (en) 2020-10-27
TWI639599B (zh) 2018-11-01
CN103608018B (zh) 2017-06-30
JP2014514297A (ja) 2014-06-19
AU2017203474A1 (en) 2017-06-08
UA114177C2 (uk) 2017-05-10
AP3751A (en) 2016-07-31
UY33984A (es) 2012-10-31
KR20140025427A (ko) 2014-03-04
CU24349B1 (es) 2018-06-05
BR112013025517A2 (pt) 2016-12-27
AR088730A1 (es) 2014-07-02
WO2012136549A1 (en) 2012-10-11
DOP2013000224A (es) 2013-11-15
US20140243295A1 (en) 2014-08-28
MA35015B1 (fr) 2014-04-03
EA027670B1 (ru) 2017-08-31
NZ615502A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
JO3733B1 (ar) استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EA201300556A1 (ru) Аминоспиртзамещенные производные 2,3-дигидроимидазо[1,2-с] хиназолина, пригодные для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
EA201300869A1 (ru) Морфинановые соединения
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
TN2015000452A1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
EA201300987A1 (ru) Фармацевтические композиции, включающие метформин и ингибитор dpp-4 или ингибитор sglt-2
TN2017000385A1 (en) Use of substituted 2,3-dihydroimidaz0[1,2-c]quinazolines.
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
GB201104267D0 (en) Pyrrolopyridineamino derivatives
MX2009003724A (es) Derivados de 2-aminocarbonil-piridina.
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
IN2014DN08886A (ar)
NZ707090A (en) Synthetic lethality and the treatment of cancer
EA201290808A1 (ru) Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения
NZ608813A (en) Treatment of myocardial infarction using tgf - beta antagonists
BR112016024332A2 (pt) métodos para o tratamento, para a determinação dos compostos a serem utilizados, para a seleção de pacientes, para a monitoração da eficácia terapêutica, para a optimização da eficácia terapêutica, para a identificação de um biomarcador, artigo de fabricação, utilização de gdc-0941, gdc-0941 e um agente de terapia endócrina e composto para a utilização
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
MX2008013477A (es) Compuestos biciclicos de tetrahidropirrol.
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201390532A1 (ru) Композиции сульфамидых ингибиторов ns3, содержащие витамин е